Abstract
Osteoporosis due to glucocorticoid-induced osteoporosis (GIOP) for inflammatory disorders continues to be a common problem. Well-distributed guidelines have provided evidence-based recommendations for management, yet many patients have little attention paid to their increased fracture risk. The purpose of this article is to discuss how new treatments for GIOP may improve overall management. Intravenous zoledronic acid (ZA), an antiresorptive agent, and teriparatide (TPT), which stimulates osteoblasts, have received US Food and Drug Administration (FDA) approval for treating GIOP. ZA is appealing because one 15-min infusion covers the patient for a year and potentially will increase the proportion of GIOP patients who are treated. TPT makes physiologic sense because GIOP is mostly due to decreased osteoblast function, and TPT stimulates osteoblasts. Although there is only one small published study in humans with GIOP, denosumab is a potentially useful antiresorptive agent, if it is approved by the FDA. The efficacy and safety of these medications in GIOP are discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
